DDrare: Database of Drug Development for Rare Diseases

265. 脂肪萎縮症
［臨床試験数：109，薬物数：164（DrugBank：59），標的遺伝子数：26，標的パスウェイ数：94］

Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 13 valent conjugated pneumococcal vaccine; 150 mg GSK1265744B; 300mg Gemcabene; 3TC; 600mg Gemcabene; ABC; ACETYL- L- CARNITINE; AKCEA-ANGPTL3-LRX; ATV; AZT; AZT/3TC; Abacavir; Abacavir 300mg twice daily; Abacavir sulfate; Abacavir sulfate, Lamivudine and Zidovudine; Acetate; Acetylcarnitine; Acipimox; Amprenavir; Antiretroviral/Anti HIV; Aramchol; Atazanavir; Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs); Atazanavir (Reyataz); Atazanavir/Ritonavir; Atorvastatin; Atorvastatin calcium; Avandia administration for 6-12 weeks; BMS-232632; Baricitinib; Behavioral: 60-minutes of steady state exercise; Behavioral: Diet; Behavioral: Exercise; Behavioral: Exercise Training; Behavioral: Exercise training; CD; CD-4 guided therapy interruption; COMBIVIR; Caffeine; Calcium; Carnitine; Cholic Acid; CoFactor; Cofactor supplementation (thiamine, riboflavin, L-carnitine); Combivir (zidovudine [AZT] / lamivudine [3TC]); Continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs); Cyclophosphamide; DIOSMIN; Device: Venus Versa; Device: poly-L-lactic acid; Didanosine; Different HAART regimens; Diosmin; Diosminex, 500 mg, tabletki powlekane; Dolutegravir; Dolutegravir 50 MG; Efavirenz; Efavirenz (EFV); Emtricitabine; Emtricitabine/tenofovir; Enfuvirtide; Enfuvirtide (T20); Fenofibrate; GSK1265744B (sodium salt) containing 14C-GSK1265744B; Gemcabene; Genetic: Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene; Genotropin (human recombinant Growth hormone); Glycerine; Growth Hormone Releasing Hormone; Growth hormone; High-carbohdyrate breakfast; High-dose REGN4461; Hu Leptin (A-100); Human growth hormone; Human recombinant leptin (metreleptin); ISIS 304801; Indinavir; Kaletra (lopinavir [LPVr]); L-Carnitine; L-Lactic acid; Lactic acid; Lamivudine; Lamivudine/Zidovudine; Leptin; Lopinavir; Lopinavir/Ritonavir; Lopinavir/ritonavir + nevirapine; Lopinavir/ritonavir + zidovudine + lamivudine; Low-Dose REGN4461; METRELEPTIN; Mecasermin; Metformin; Metformin hydrochloride; Metreleptin; Metrelpetin; Monotherapy (Lopinavir/ritonavir); Monotherapy (Lopinavir/ritonavir) + ABC/3TC; Myalept; Nelfinavir; Nelfinavir mesylate; Nevirapine; Niacin; Non-nucleoside reverse transcriptase inhibitors; Norvir; NucleomaxX; Nucleoside analogue sparing HAART regimen; Nucleoside reverse transcriptase inhibitors; Obeticholic Acid; Obeticholic acid; Other: Glycerine gel; Other: Observation; POLY-L-LACTIC ACID; Perform blood cells and fibroblasts biochemical and immuno-labeled investigations; Pioglitazone; Pioglitazone or metformin; Pneumococcal polysaccharide vaccine 23 valent; Pravastatin; Pravastatin sodium; Prevenar13; Procedure: testosterone injection; Protease inhibitor; Protease inhibitors; R-metHuLeptin; REYATAZ 150MG 60 CPS BL; RTV; Raltegravir; Recombinant human growth hormone; Recombinant human growth hormone + rosiglitazone; Reyataz; Riboflavin; Ritonavir; Ritonavir (Norvir); Rosiglitazone; Rosiglitazone maleate; ST200; SUSTIVA; Saquinavir; Serostim®[somatropin (rDNA origin) for injection]; Setmelanotide; Simvastatin; Somatropin; Standard continuous antiretroviral therapy; Stavudine; Sulfate; TAT4 Gel concentration A; TAT4 Gel concentration B; TH9507; TRUVADA; Tenofovir; Tenofovir DF; Tenofovir Disoproxil Fumarate; Tenofovir disoproxil; Tesamorelin; Tesamorelin (Egrifta); Testosterone; Thiamine; Tipranavir; Total Dietary Replacement; Use of lipid-lowering drugs.; VOLANESORSEN SODIUM, ApoC-III Antisense Oligonucleotide; Viral load driven treatment interruption; Volanesorsen; Zidovudine; [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01612858 (ClinicalTrials.gov)	June 2011	4/6/2012	Metabolic Abnormalities in HIV-infected Persons	Metabolic Abnormalities in HIV-infected Persons	Lipodystrophy;HIV Infection	Drug: Metformin;Drug: Pioglitazone	Tufts Medical Center	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	70 Years	All	20	Phase 4	United States
2	NCT01023620 (ClinicalTrials.gov)	October 2009	30/11/2009	HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)	Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations	HIV Infections	Drug: Pioglitazone;Other: Observation	University of Texas Southwestern Medical Center	Takeda Pharmaceuticals North America, Inc.	Completed	18 Years	N/A	Male	4	N/A	United States
3	NCT00362440 (ClinicalTrials.gov)	August 2006	9/8/2006	Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome	A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial	HIV Lipodystrophy	Drug: Leptin;Drug: Pioglitazone or metformin;Drug: Placebo	Beth Israel Deaconess Medical Center	American Diabetes Association	Completed	18 Years	N/A	All	9	Phase 2	United States
4	NCT00656851 (ClinicalTrials.gov)	September 2005	10/4/2008	Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome	Myocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic Syndrome	HIV Infections;Cardiovascular Disease;Insulin Resistance;HIV Lipodystrophy;The Metabolic Syndrome	Drug: Pioglitazone;Behavioral: Exercise Training	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	28 Years	50 Years	All	24	N/A	United States
5	NCT00639457 (ClinicalTrials.gov)	January 2005	18/3/2008	Exercise and Pioglitazone for HIV-Metabolic Syndromes	Exercise and Pioglitazone for HIV-Metabolic Syndromes	HIV Infections;Type 2 Diabetes;Obesity;HIV;AIDS;Cardiovascular Disease;Lipodystrophy	Drug: Pioglitazone;Behavioral: Exercise training	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	18 Years	65 Years	All	44	N/A	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00148850 (ClinicalTrials.gov)	February 2003	7/9/2005	Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients	A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study	HIV-Associated Lipodystrophy Syndrome;HIV Infections	Drug: Pioglitazone	French National Agency for Research on AIDS and Viral Hepatitis	Takeda	Terminated	18 Years	N/A	Both	130	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01612858
(ClinicalTrials.gov)

June 2011

4/6/2012

Metabolic Abnormalities in HIV-infected Persons

Lipodystrophy;HIV Infection

Drug: Metformin;Drug: Pioglitazone

Tufts Medical Center

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

18 Years

70 Years

All

Phase 4

United States

NCT01023620
(ClinicalTrials.gov)

October 2009

30/11/2009

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations

HIV Infections

Drug: Pioglitazone;Other: Observation

University of Texas Southwestern Medical Center

Takeda Pharmaceuticals North America, Inc.

Completed

18 Years

N/A

Male

N/A

United States

NCT00362440
(ClinicalTrials.gov)

August 2006

9/8/2006

Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome

A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial

HIV Lipodystrophy

Drug: Leptin;Drug: Pioglitazone or metformin;Drug: Placebo

Beth Israel Deaconess Medical Center

American Diabetes Association

Completed

18 Years

N/A

All

Phase 2

United States

NCT00656851
(ClinicalTrials.gov)

September 2005

10/4/2008

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

Myocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic Syndrome

HIV Infections;Cardiovascular Disease;Insulin Resistance;HIV Lipodystrophy;The Metabolic Syndrome

Drug: Pioglitazone;Behavioral: Exercise Training

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NULL

Completed

28 Years

50 Years

All

N/A

United States

NCT00639457
(ClinicalTrials.gov)

January 2005

18/3/2008

Exercise and Pioglitazone for HIV-Metabolic Syndromes

HIV Infections;Type 2 Diabetes;Obesity;HIV;AIDS;Cardiovascular Disease;Lipodystrophy

Drug: Pioglitazone;Behavioral: Exercise training

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NULL

Completed

18 Years

65 Years

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00148850
(ClinicalTrials.gov)

February 2003

7/9/2005

Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients

A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study

HIV-Associated Lipodystrophy Syndrome;HIV Infections

Drug: Pioglitazone

French National Agency for Research on AIDS and Viral Hepatitis

Takeda

Terminated

18 Years

N/A

Both

130

Phase 3

France